Blueprint
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of
1934
January
31, 2018
Commission
File Number 001-14978
SMITH & NEPHEW
plc
(Registrant's
name)
15 Adam
Street
London, England WC2N 6LA
(Address
of registrant's principal executive offices)
[Indicate
by check mark whether the registrant files or will file
annual
reports
under cover Form 20-F or Form 40-F.]
Form
20-F
X
Form 40-F
---
---
[Indicate
by check mark if the registrant is submitting the Form 6-K
in
paper
as permitted by Regulation S-T Rule 101(b)(1).]
Yes
No X
---
---
[Indicate
by check mark if the registrant is submitting the Form 6-K
in
paper
as permitted by Regulation S-T Rule 101(b)(7).]
Yes
No X
---
---
[Indicate
by check mark whether by furnishing the information
contained
in this
Form, the registrant is also thereby furnishing information to
the
Commission
pursuant to Rule 12g3-2 (b) under the Securities Exchange Act
of
1934.]
Yes
No X
---
---
If
"Yes" is marked, indicate below the file number assigned to
the
registrant
in connection with Rule 12g3-2 (b) : 82- n/a.
Appointment of Roland Diggelmann as Non-Executive
Director
31 January 2018
Smith & Nephew (LSE: SN, NYSE: SNN), the global medical
technology business, announces that Roland Diggelmann is to join
its Board as Non-Executive Director on 1 March 2018.
Roland Diggelmann, Chief Executive Officer at Roche Diagnostics and
a member of the Corporate Executive Committee of F. Hoffmann-La
Roche Ltd, joined Roche in 2008 as Head Region Asia Pacific, and
was appointed to his current role in 2012. Prior to Roche, he was
Managing Director for Japan and later Executive Vice President
Sales/Distribution EMEA and Managing Director for Zimmer GmbH.
Before Zimmer he worked for Sulzer Orthopedics Ltd and Sulzer
Medical/Centerpulse Ltd in Europe and Asia Pacific, prior to its
acquisition by Zimmer.
Roland Diggelmann is a Swiss citizen, born in 1967, and studied
Business Administration at University of Berne,
Switzerland.
Roberto Quarta, Chairman of Smith & Nephew,
commented:
"As we have said previously, we have been looking to strengthen our
Board with a Non-Executive Director who has direct experience in
our orthopaedic field of medical devices. Roland Diggelmann brings
that experience to the Board, having held senior positions at
Sulzer Orthopaedics and then with Zimmer. He has also had
significant international experience, particularly in Japan and
other parts of Asia, important markets for Smith & Nephew. We
are delighted that he will be joining our Board and look forward to
his insights into our industry."
No disclosure obligations arise under paragraphs (1) to (6) of LR
9.6.13 R of the UK Listing Authority's Listing Rules in respect of
this appointment. Mr Diggelmann's fees will be $129,780 per annum
of which $9,780 will be paid in the form of Smith & Nephew
shares in-line with current Non-Executive
Directors.
- ends
-
Enquiries
|
InvestorsIngeborg OieSmith & Nephew
|
+44 (0) 20 960 2285
|
|
MediaCharles ReynoldsSmith & Nephew
|
+44 (0) 1923
477314
|
|
Ben
Atwell / Simon ConwayFTI Strategic Consulting
|
+44 (0)
20 3727 1000
|
About Smith & Nephew
Smith
& Nephew is a global medical technology business dedicated to
helping healthcare professionals improve people's lives. With
leadership positions in Orthopaedic
Reconstruction, Advanced Wound
Management, Sports Medicine
and Trauma
& Extremities, Smith & Nephew has around 15,000
employees and a presence in more
than 100 countries. Annual sales in 2016 were almost $4.7
billion. Smith & Nephew is a member of the FTSE 100 (LSE:SN,
NYSE:SNN).
For
more information about Smith & Nephew, please visit our website
www.smith-nephew.com, follow @SmithNephewplc
on Twitter or
visit
SmithNephewplc on Facebook.com.
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading margins, market trends and our product
pipeline are forward-looking statements. Phrases such as "aim",
"plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission
under the U.S. Securities Exchange Act of 1934, as amended,
including Smith & Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.
◊ Trademark of
Smith & Nephew. Certain marks registered US Patent and
Trademark Office.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Smith
& Nephew Plc
(Registrant)
Date: January
31, 2018
By: /s/
Susan Swabey
-----------------
Susan
Swabey
Company
Secretary